Busy In-Tray Awaits New EFPIA Boss Nathalie Moll
Executive Summary
Nathalie Moll, secretary general of biotech industry body EuropaBio, is to be the next director general of EFPIA, the federation that represents the R&D-based pharmaceutical industry in Europe. With issues such as the forthcoming Brexit negotiations, the EU’s inquiry into medicines access and pricing, and the implementation of the new Clinical Trials Regulation, EFPIA’s new leader will have a lot of weighty dossiers to deal with.
You may also be interested in...
EU Exclusivity Review: Commission To Assess Impact On 'Skyrocketing' Drug Prices
Analysis will consider effect of incentives such as data exclusivity and supplementary protection certificates on drug prices, availability and access to medicines; European health ministers also pledge cooperation rein in what they see as the very high prices of some medicines.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.